A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension

This study is looking at the real-world effectiveness and safety of dapagliflozin — a medication used to treat type 2 diabetes — in patients who also have high blood pressure (hypertension). Dapagliflozin belongs to a class of drugs called SGLT2 inhibitors, which lower blood sugar by causing the kidneys to remove glucose through the urine. It may also have benefits for blood pressure and heart health. This is an observational study following patients already prescribed this medication. **You may be eligible if...** - You have been diagnosed with both type 2 diabetes and hypertension - Your doctor has already prescribed dapagliflozin (Trudapa or Trudapa M SR tablets) for you - You are able to participate for the full duration of the study - You have given written consent to participate **You may NOT be eligible if...** - You have secondary hypertension (high blood pressure caused by another specific medical condition such as kidney artery narrowing, adrenal tumors, or Cushing's syndrome) - You have taken dapagliflozin within the last 4 weeks before your baseline visit - You are expected to need insulin during the study - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.